Results 161 to 170 of about 3,430 (200)

Radiosynthesis of the Iodine-124 Labeled Hsp90 Inhibitor PU-H71 [PDF]

open access: yesJournal of Labelled Compounds and Radiopharmaceuticals, 2016
Heat shock protein 90 (Hsp90) is an ATP dependent molecular chaperone protein whose function is critical for maintaining several key proteins involved in survival and proliferation of cancer cells. PU-H71 (1), is a potent purine-scaffold based ATP pocket
Jason S. Lewis   +2 more
exaly   +4 more sources

The Novel HSP90 Inhibitor, PU-H71, Suppresses Glial Cell Activation but Weakly Affects Clinical Signs of EAE [PDF]

open access: yesJournal of Neuroimmunology, 2013
Ansamycins are very effective HSP90 inhibitors that showed significant beneficial effects in the treatment of EAE. However, their toxicity and poor stability in solution limit their clinical use.
Cinzia Dello Russo   +2 more
exaly   +4 more sources

PU-H71: An Improvement on Nature's Solutions to Oncogenic Hsp90 Addiction

open access: yesPharmacological Research, 2015
Despite recent advances in precision medicine, many molecular-based antineoplastic agents do not potentiate sustainable long term remissions, warranting the investigation of novel therapeutic strategies. Heat shock protein 90 (Hsp90) is a molecular chaperone that not only has oncogenic properties, but also has distinct expression profiles in malignant ...
Matthew Trendowski
exaly   +3 more sources

HPLC Method Development, Validation and Impurity Characterization for an Antitumor Hsp90 Inhibitor—PU-H71 (NSC 750424) [PDF]

open access: yesJournal of Pharmaceutical and Biomedical Analysis, 2014
An HPLC method for the assay of the heat shock protein 90 inhibitor, PU-H71 (NSC 750424), has been developed and validated. The stress testing of PU-H71 was carried out in accordance with ICH guidelines Q1A (R2) under aqueous, acidic, alkaline, oxidative, thermolytic and photolytic conditions.
Paul Liu
exaly   +3 more sources

PU-H71, a Novel Hsp90 Inhibitor, as a Potential Cancer-Specific Sensitizer to Carbon-Ion Beam Therapy [PDF]

open access: yesJournal of Radiation Research, 2016
Abstract PU-H71, a heat shock protein 90 (Hsp90) inhibitor, has yielded therapeutic efficacy in many preclinical models and is currently in clinical trials. Carbon-ion radiotherapy (CIRT) has provided successful tumor control; however, there is still room for improvement, particularly in terms of tumor-specific radiosensitization.
MATSUMOTO Yoshitaka   +2 more
exaly   +3 more sources
Some of the next articles are maybe not open access.

Related searches:

Using 124I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.

Journal of Clinical Oncology, 2013
11076 Background: PU-H71 is a Heat Shock Protein 90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU-H71) region of interest analysis and dilution principle. A microdose pilot study has shown uptake of *PU-H71 in a variety of tumors.
John F. Gerecitano   +15 more
openaire   +1 more source

Home - About - Disclaimer - Privacy